Skip to main content


head uk2

Publications in April 2011

In April the rate of publications with chitosan slightly dropped. 90 articles were published which means 7 less than in April 2010. In comparison to March 2011 38 fewer papers presented results in chitosan research.

Strongest nations in terms of number of publications have been China, India and the USA. In Germany 3 research institutions published their results ril.

Top Journals Publications
Drug Deliv 7
Acta Biomater 4
J Mater Sci Mater Med  
J Biomed Mater Res B Appl Biomater  
Int J Biol Macromol  

Tabelle: Journals with the most publications about chitosan and its derivatives

Below 2 of the 3 German publications are presented:

Neuronal and glial responses to siRNA-coated nerve guide implants in vitro

N. Hoffmann; U. Mittnacht; H. Hartmann; Y. Baumer; J. Kjems; S. Oberhoffner; B. Schlosshauer

Hoffmann et al. has oriented its research focus on the healing of damages of the nervous system. Neural defects are able to heal; one way is the implantation of nerve guide implants. They enhance the cross-linking growth of axons. In the resent paper polydioxanon polymer filaments were coated with chitosan/siRNA nano-particles and their impacts on neuronal and Schwann cells were observed.
The Hoffmann team came to the following results:

  1. Glial cell motility has not been affected.
  2. The axonal growth was not influenced.
  3. Only slight proliferations were observed.
  4. The application did not induce inflammatory responses hamper that might have negative impacts on axonal regeneration.

Hoffmann et al. conclude that chitosan/siRNA-coated polymer filaments would be suitable for biohybride implants, because they do not show significant negative effects on neuronal and glial cells.

Source: Sciencedirect


Development of a biodegradable tissue adhesive based on functionalized 1,2-ethylene glycol bis(dilactic acid). II

H.W. Rohm; C. Lurtz C; J. Wegmann; E.K. Odermatt; D. Behrend; K.P. Schmitz; K. Sternberg

Tissue adhesives are a suitable alternative to mechanical tissue sutures or staplers. Rohm et al. tested a two-component adhesive consisting of:

  1. 1,2-ethylene glycol bis (functionalized with hexamethylene diisocyanate)
  2. Chitosan chloride (Chitosan HCl)

In in vitro and in vivo tests Rohm et al. compared the properties of the novel adhesive with “Tissucol Duo S. Immuno fibrin glue” (Baxter Deutschland GmbH). They demonstrated that its adhesive strength is significantly higher than from the fibrin glue. If the exposure time is increased from 10 minutes to 48 hours the tensile strength augments for the novel adhesive.
In contrast to fibrin glue, joint tissues treated with the chitosan mixture can be corrected within a time frame of three minutes. In addition, Rohm et al. points out the results of biocompatibility studies and notes that the chitosan/siRNA adhesive had no toxic side effects on the surrounding tissue.

Source: Wiley Online Library

Source: gopubmed (April 4,2011)

chitosan, implants, Crosslinking, Schwann cells

  • Created on .

Congress and fairs

Meet us in person 2024:

  • 14th PBP World Meeting/ Research Pharm, Vienna, Austria, 18.-21.03.2024
  • EPNOE Workshop on Analytics of Polysaccharides, ETH Zürich, Zürich, Switzerland, 25.-26.06.2024
  • CPHI, Milan, Italy, 08.-10.10.2024
  • MEDICA 2024, Düsseldorf, Germany, 11.-14.11.2024

To arrange an appointment please contact Katja Richter via This email address is being protected from spambots. You need JavaScript enabled to view it.


  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.